Exportar Publicação

A publicação pode ser exportada nos seguintes formatos: referência da APA (American Psychological Association), referência do IEEE (Institute of Electrical and Electronics Engineers), BibTeX e RIS.

Exportar Referência (APA) 
Mello-Sampayo, F. de., Vale, S. de S. & Camões, F. (2013). Substitutability between drugs, innovation and growth in the pharmaceutical industry. In 10th EBES Conference Proceedings. (pp. 13-28). Istanbul: EBES.
Exportar Referência (IEEE) 
F. D. Sampayo et al.,  "Substitutability between drugs, innovation and growth in the pharmaceutical industry", in 10th EBES Conf. Proc., Istanbul, EBES, 2013, pp. 13-28
Exportar BibTeX 
@inproceedings{sampayo2013_1722105430405,
	author = "Mello-Sampayo, F. de. and Vale, S. de S. and Camões, F.",
	title = "Substitutability between drugs, innovation and growth in the pharmaceutical industry",
	booktitle = "10th EBES Conference Proceedings",
	year = "2013",
	editor = "",
	volume = "",
	number = "",
	series = "",
	pages = "13-28",
	publisher = "EBES",
	address = "Istanbul",
	organization = "EBES",
	url = "https://ebesweb.org/proceedings/"
}
Exportar RIS 
TY  - CPAPER
TI  - Substitutability between drugs, innovation and growth in the pharmaceutical industry
T2  - 10th EBES Conference Proceedings
AU  - Mello-Sampayo, F. de.
AU  - Vale, S. de S.
AU  - Camões, F.
PY  - 2013
SP  - 13-28
CY  - Istanbul
UR  - https://ebesweb.org/proceedings/
AB  - This paper establishes a relationship between the elasticity of demand for pharmaceutical intermediates and the growth rate for these intermediates variety. We build a model that contains two sectors, one final good sector producing treatments, and one intermediate goods sector producing a differentiated input used in the final treatment. The effects on the medicaments varieties' growth rate of the introduction of a fiscal instrument over pharmaceutical producers' profits are discussed. When the fiscal instrument is a tax over intermediate firms' profits, R&D by firms in the pharmaceutical goods sector results in positive growth provided there is enough substitutability among intermediates assured by a patent system. Otherwise, a subsidy over pharmaceutical firms' profits should be considered to generate positive growth of innovation in medicaments.
ER  -